{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Possibly Marketed Outside US
Source:
21 CFR 356
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 356
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M006
(2020)
Source URL:
First approved in 2020
Source:
M006
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Midamaline was used as a local anesthetic. Information about the current use of this compound is not available.
Status:
Possibly Marketed Outside US
Source:
CLO2--Portable sterilization card by Shenzhen Haiyin Hongye Technology Co., Ltd.
(2020)
Source URL:
First approved in 2020
Source:
CLO2--Portable sterilization card by Shenzhen Haiyin Hongye Technology Co., Ltd.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Golotimod (SCV-07) is compound that has been investigated as a medicine for the treatment of tuberculosis, and various other viral and bacterial infections. Golotimod acts broadly on the Toll-like receptor (TLR) pathway. It stimulates the T-helper 1 (Th1) type immune response and blocks signal transducers and activator of transcription 3 (STAT3) mediated signaling. Treatment of tuberculosis with golotimod improves clearance of mycobacteria, cavity healing, and immune parameters and also reduced symptoms (such as fever, weakness, sweating, dry cough, productive cough, dyspnea, chest pain, tachycardia) without adverse effects. Phase II clinical trials have been completed to assess its safety and tolerability.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333C
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Dymanthine (Thelmesan) is an Anthelmintic, it is prepared as the hydrochloride and has some activity against hookworm infection, ascariasis, trichuriasis and hymenolepiasis. The drug appears to be safe, well tolerated and to cause few side effects (nausea, vomiting, headache, diarrhea, giddiness).
